CCO Oncology Podcast

Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma

Episode Summary

Experts discuss the role of BCMA-targeted therapy for patients with multiple myeloma, including their experiences and challenges with implementing these approaches in clinical practice.

Episode Notes

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: 

• Considerations with administration, including access challenges
• Sequencing Therapies
• Future developments with BCMA-targeted therapies

Presenters:

Suzanne Lentzsch, MD, PhD
Professor of Medicine
Division of Hematology/Oncology
Director, Multiple Myeloma and Amyloidosis Program
Columbia University Medical Center 
New York, New York

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.

Link to full program: bit.ly/41YEOO6